These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 39048762)

  • 1. MASCC/ISOO Clinical Practice Statement: The risk of secondary oral cancer following hematopoietic cell transplantation.
    Raber-Durlacher JE; Treister NS; Zadik Y; Dean DR; Miranda-Silva W; Fregnani ER; Epstein JB; Elad S
    Support Care Cancer; 2024 Jul; 32(8):545. PubMed ID: 39048762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MASCC/ISOO Clinical Practice Statement: Management of oral manifestations of chronic graft-versus-host-disease.
    Zadik Y; Raber-Durlacher JE; Epstein JB; Majorana A; Laheij A; Bardellini E; Blijlevens N; Elad S
    Support Care Cancer; 2024 Jul; 32(8):546. PubMed ID: 39048807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MASCC/ISOO clinical practice statement: Current understanding on controversies in basic oral care in hemato-oncology and hematopoietic cell transplantation.
    Raber-Durlacher JE; Zadik Y; Treister NS; Stempler N; Bruno JS; Epstein JB; Elad S
    Support Care Cancer; 2024 Jul; 32(8):550. PubMed ID: 39048882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MASCC/ISOO Clinical Practice Statement: Management of oral complications of targeted therapy.
    Villa A; Epstein JB; Yarom N; Hong C; Fulop C; Bossi P; Elad S
    Support Care Cancer; 2024 Jul; 32(8):549. PubMed ID: 39048808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MASCC/ISOO Clinical Practice Statement: Clinical assessment of salivary gland hypofunction and xerostomia in cancer patients.
    Hong C; Epstein JB; Jensen SB; Gueiros LA; van Leeuwen SJM; Kandwal A; Vissink A; Elad S
    Support Care Cancer; 2024 Jul; 32(8):551. PubMed ID: 39048727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MASCC/ISOO Clinical Practice Statement: Management of salivary gland hypofunction and xerostomia in cancer patients.
    Hong C; Jensen SB; Vissink A; Bonomo P; Santos-Silva AR; Gueiros LA; Epstein JB; Elad S
    Support Care Cancer; 2024 Jul; 32(8):548. PubMed ID: 39048728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Chronic graft-versus-host-disease involving the oral mucosa: clinical presentation and treatment].
    Elad S; Levitt M; M Y S
    Refuat Hapeh Vehashinayim (1993); 2008 Nov; 25(4):19-27, 72. PubMed ID: 19263864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuing increased risk of oral/esophageal cancer after allogeneic hematopoietic stem cell transplantation in adults in association with chronic graft-versus-host disease.
    Atsuta Y; Suzuki R; Yamashita T; Fukuda T; Miyamura K; Taniguchi S; Iida H; Uchida T; Ikegame K; Takahashi S; Kato K; Kawa K; Nagamura-Inoue T; Morishima Y; Sakamaki H; Kodera Y;
    Ann Oncol; 2014 Feb; 25(2):435-41. PubMed ID: 24399081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MASCC/ISOO Clinical Practice Statement: Adjuvant bone-modifying agents in primary breast cancer patients - prevention of medication-related osteonecrosis of the jaw.
    Yarom N; Van Poznak CH; Epstein JB; Ottaviani G; Matsuda Y; Migliorati C; Elad S
    Support Care Cancer; 2024 Jul; 32(8):547. PubMed ID: 39048887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic instability after allogeneic hematopoietic cell transplantation is frequent in oral mucosa, particularly in patients with a history of chronic graft-versus-host disease, and rare in nasal mucosa.
    Khan FM; Sy S; Louie P; Ugarte-Torres A; Berka N; Sinclair GD; Stewart DA; Russell JA; Storek J
    Blood; 2010 Sep; 116(10):1803-6. PubMed ID: 20548092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extracorporeal photophoresis: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2006; 6(6):1-82. PubMed ID: 23074497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subjective Oral Dryness following Hematopoietic Cell Transplantation: A Report from the Orastem Study.
    Bulthuis MS; van Leeuwen SJM; Thomas RZ; van Gennip LLA; Whiteside HM; Isom S; Kline DM; Laheij AMGA; Raber-Durlacher JE; Hasséus B; Johansson JE; Hovan AJ; Brennan MT; von Bültzingslöwen I; Huysmans MDNJM; Blijlevens NMA
    Transplant Cell Ther; 2024 Apr; 30(4):446.e1-446.e11. PubMed ID: 38242439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severity of Chronic Graft-versus-Host Disease and Late Effects Following Allogeneic Hematopoietic Cell Transplantation for Adults with Hematologic Malignancy.
    Lee CJ; Wang T; Chen K; Arora M; Brazauskas R; Spellman SR; Kitko C; MacMillan ML; Pidala JA; Badawy SM; Bhatt N; Bhatt VR; DeFilipp Z; Diaz MA; Farhadfar N; Gadalla S; Hashmi S; Hematti P; Hossain NM; Inamoto Y; Lekakis LJ; Sharma A; Solomon S; Lee SJ; Couriel DR
    Transplant Cell Ther; 2024 Jan; 30(1):97.e1-97.e14. PubMed ID: 37844687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral epithelial dysplasia and squamous cell carcinoma following allogeneic hematopoietic stem cell transplantation: clinical presentation and treatment outcomes.
    Mawardi H; Elad S; Correa ME; Stevenson K; Woo SB; Almazrooa S; Haddad R; Antin JH; Soiffer R; Treister N
    Bone Marrow Transplant; 2011 Jun; 46(6):884-91. PubMed ID: 21460866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A case report of secondary oral squamous cell carcinoma after allogeneic hematopoietic stem cell transplantation.
    Liu Z; Peng Y; Yong X; Mei G; Yang Y; Yi C; Tao R
    Oral Oncol; 2020 Oct; 109():104629. PubMed ID: 32165139
    [No Abstract]   [Full Text] [Related]  

  • 16. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
    Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
    Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extensive dental caries in patients with oral chronic graft-versus-host disease.
    Castellarin P; Stevenson K; Biasotto M; Yuan A; Woo SB; Treister NS
    Biol Blood Marrow Transplant; 2012 Oct; 18(10):1573-9. PubMed ID: 22516054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral malignancies following HSCT: graft versus host disease and other risk factors.
    Demarosi F; Lodi G; Carrassi A; Soligo D; Sardella A
    Oral Oncol; 2005 Oct; 41(9):865-77. PubMed ID: 16084755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secondary oral cancer following hematopoietic cell transplantation.
    Santarone S; Natale A; Angelini S; Papalinetti G; Vaddinelli D; Di Bartolomeo A; Di Bartolomeo P
    Bone Marrow Transplant; 2021 May; 56(5):1038-1046. PubMed ID: 33235350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.